phrykt

TherapeuticsMD, Inc. (TXMD): who owns it and who trades it

As of Nov 16, 2026, TXMD insiders reported 1 purchase worth $14K in the last 12 months. The largest buyer was Tommy G Thompson (Director), with $14K. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling TherapeuticsMD

From the latest filings

Overall: about as much buying as selling. Famous investors mostly sold. Insiders mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Insider trades

In the last 12 months, TXMD insiders reported $14K of open-market purchases and $0 of sales.

Purchases, 12 months
$14K
1 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Dec 23, 2025
Filed Dec 29, 2025

Purchases and sales by month

$14K$14KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Dec 23, 2025Tommy G ThompsonDirectorPurchase8,400$1.67$14KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Tommy G ThompsonDirector$14K–Dec 23, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TXMD short interest

Low short interest. 0.3% of TXMD shares are sold short: about 1 share in 370. Over the last 12 reports the number of shares short went down 41%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 31,319 TXMD shares were sold short, 0.3% of the shares outstanding, up 27.0% from the report before. At the average daily volume of 21,273 shares, buying them all back would take about 1.5 trading days (days to cover).

Shares short, % of all shares

0.27%May 15Oct 300.53%

Days to cover

1.5May 15Oct 303.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202631,3190.27%+27%21,2731.5
Oct 15, 202624,6640.21%+4%17,3301.4
Sep 30, 202623,6630.20%-10%17,0141.4
Sep 15, 202626,4370.23%+0%20,8591.3
Aug 31, 202626,3870.23%-4%46,9261.0
Aug 14, 202627,6180.24%-5%14,9821.8
Jul 31, 202629,1410.25%-32%21,4171.4
Jul 15, 202643,1710.37%-24%27,3881.6
Jun 30, 202656,5480.49%+23%36,3551.6
Jun 15, 202646,1480.40%-10%100,0111.0
May 29, 202651,4120.44%-3%15,7123.3
May 15, 202653,0830.46%-6%22,7382.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

TherapeuticsMD company events

TherapeuticsMD filed 5 reports on Form 8-K in the last 12 months, 1 of them about an important change (auditor). The latest was on Aug 11, 2026.

  1. Aug 11, 2026ResultsReleased financial results. Filing
  2. May 12, 2026ResultsReleased financial results. Filing
  3. Mar 30, 2026ResultsReleased financial results. Filing
  4. Jan 21, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  5. Dec 16, 2025VoteReported shareholder vote results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

TherapeuticsMD financials

Famous investors that hold TXMD

2 of the 50 well-known investors we track reported holding TXMD in their latest 13F filing. The largest position is Jim Simons's, worth $289K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026142,199$289K0.0%-3%
Ken Griffin · Citadel AdvisorsQ3 202664,787$132K0.0%-25%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about TherapeuticsMD, Inc. (TXMD) stock

Are TXMD insiders buying or selling?

In the last 12 months, TXMD insiders reported 1 open-market purchase worth $14K and no sales. The latest trade was on Dec 23, 2025. See every trade.

What is the short interest in TXMD?

As of Oct 30, 2026, 31,319 TXMD shares were sold short, 0.3% of the shares outstanding, up 27.0% from the report before. At the average daily volume of 21,273 shares, buying them all back would take about 1.5 trading days (days to cover). See the history.

Which famous investors hold TXMD?

2 of the 50 well-known investors we track reported TXMD in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $289K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.